Palazestrant

SKU: orb1744552

Description

Palazestrant (OP-1250) is an orally bioavailable, complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD). It potently blocks estrogen-driven proliferation in breast cancer cell lines like MCF-7 and shows antitumor efficacy in vivo models of ER+ breast cancer, supporting its research use for metastatic disease.

Research Area

Metabolism Research

Key Properties

• CAS Number: 2092925-89-6
• MW: 449.6
• Purity: 97.55% (May vary between batches)
• Formula: C₂₈H₃₆FN₃O
• SMILES: C(C(C)(C)F)N1[C@@H](C2=C(C=3C(N2)=CC=CC3)C[C@H]1C)C4=CC=C(OC5CN(CCC)C5)C=C4
• Target: Estrogen Receptor/ERR,Estrogen/progestogen Receptor

Bioactivity

• Target IC50:
  17b-estradiol (E2):6.4 nM

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ER, Estrogen Receptor, EstrogenReceptor, OP1250, OP-1250, OP 1250, progestogenReceptor, progestogen Receptor

Compound Identifiers

PubChem CID

135351887